XML 39 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Data (Tables)
 6 Months Ended
Mar. 28, 2014
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Business Segment
Selected information by business segment was as follows:

Three Months Ended
 
Six Months Ended

March 28,
2014

March 29,
2013
 
March 28,
2014
 
March 29,
2013
Net sales:



 
 
 
 
Specialty Pharmaceuticals
$
324.3


$
344.4

 
$
633.8

 
$
604.6

Global Medical Imaging
222.4


229.1

 
441.0

 
458.8

Net sales of operating segments (1)
546.7


573.5

 
1,074.8

 
1,063.4

Other (2)
11.1


11.8

 
23.2

 
25.9

Net sales
$
557.8


$
585.3

 
$
1,098.0

 
$
1,089.3

Operating income:



 
 
 
 
Specialty Pharmaceuticals
$
105.9


$
105.0

 
$
218.9

 
$
140.0

Global Medical Imaging
10.3


18.9

 
14.7

 
68.0

Segment operating income
116.2


123.9

 
233.6

 
208.0

Unallocated amounts:





 
 
 
 
Corporate and allocated expenses (3)          
(72.7
)

(40.3
)
 
(97.9
)
 
(65.7
)
Intangible asset amortization
(15.5
)

(8.8
)
 
(24.3
)
 
(17.7
)
Restructuring and related charges, net (4)
(21.7
)

(6.9
)
 
(29.8
)
 
(7.9
)
Separation costs
(2.6
)

(14.4
)
 
(4.8
)
 
(26.4
)
Operating income
$
3.7

 
$
53.5

 
$
76.8

 
$
90.3

(1)
Amounts represent sales to external customers.
(2)
Represents products that were sold to Covidien, our former parent company, which is discussed in Note 14.
(3)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(4)
Includes restructuring-related accelerated depreciation of $0.5 million for the three months ended March 29, 2013 and $0.1 million and $1.3 million million for the six months ended March 28, 2014 and March 29, 2013, respectively. Restructuring-related accelerated depreciation for the three months ended March 28, 2014 was immaterial.